02339nas a2200457   4500000000100000008004100001260001300042653001500055653001000070653000900080653001000089653002100099653001600120653001200136653003300148653003000181653001600211653001100227653001100238653001100249653001200260653000900272653001600281653001400297653001500311653001300326100001500339700001100354700001500365700001600380700001400396700001600410700001200426245009000438856005900528300001000587490000700597050003200604520123100636022001401867       1994                            d  c1994 Mar10aAdolescent10aAdult10aAged10aChild10aChild, Preschool10aClofazimine10aDapsone10aDrug Administration Schedule10aDrug Therapy, Combination10aEthionamide10aFemale10aHumans10aInfant10aleprosy10aMale10aMiddle Aged10aPrognosis10aRecurrence10aRifampin1 aPattyn S R1 aGhys P1 aJanssens L1 aTshilumba K1 aKuykens L1 aKaribushi N1 aDenis P00aA randomized clinical trial of two single-dose treatments for paucibacillary leprosy.  uhttp://leprev.ilsl.br/pdfs/1994/v65n1/pdf/v65n1a04.pdf  a45-570 v65  aInfolep Library - available3 a<p>We compared 2 single-dose regimens for the treatment of paucibacillary leprosy in a randomized clinical trial in Zaïre. The regimens were: C2 (rifampicin 40 mg/kg and 1200 mg clofazimine once) and C4 (rifampicin 40 mg/kg, clofazimine 100 mg, DDS 100 mg and ethionamide 500 mg once). An analysis of the results of patients enrolled between May 1987 and December 1988, with a maximum follow-up of 4 years, is presented. A total of 622 patients were enrolled and 14 paucibacillary and 1 multibacillary relapses occurred. The overall paucibacillary relapse rate was 2.4 per 100 person years. This relapse rate was higher for older patients as well as for patients with 3 or more lesions. The probability of cure at 3 years is 0.816 for C2 and 0.823 for C4, the difference not being statistically significant. The probability of cure at 3 years with either regimen is higher for patients with 1 or 2 lesions (0.872) than for patients with 3 or more lesions (0.787), and it is higher for patients with a bacterial index of 0 (0.831) than for patients with a bacterial index of 1 (0.699). These results are compared to other studies. We also discuss the potential of single-dose treatment regimens for paucibacillary leprosy.</p>  a0305-7518